Sage Therapeutics, Inc. logo

Sage Therapeutics, Inc.

SAGE Therapeutics is developing novel medicines to treat central nervous system disorders. Sage Therapeutics (Nasdaq: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders.

[stock_market_widget type=”leaderboard” template=”color-frame” color=”yellow” assets=”SAGE” api=”yf” style=”font-size: 15px”]

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.sagerx.com
Founded2010
Disease Focus
Development StageClinical
STOCK CODENASDAQ: SAGE
Address
215 First Street, MA 02142
Cambridge
United States
Email
Contact Number
+1 617-299-8380

In Oct 2011, SAGE inlicenses Ligands Platform Captisol technology in order to produce its key molecules including SAGE-547. Under the terms, Ligand Pharmaceuticals is entitled to receive a 3% royalty sales plus additional milestone payments.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/sage-therapeutics” connections=”true” suffix=””]

SAGE drug discovery platform enables the design and identification of highly selective and potent allosteric modulators of GABAA or NMDA receptors. Its allosteric modulator chemistry platform _called the Positive and Negative Allosteric Modulator (PANAM) platform which can generate new chemical entities.